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ABSTRACT The effect of administration of DBO-83 on memory processes was evaluated in the mouse
passive avoidance test. DBO-83 (1–5 mgkg–1 ip) prevented amnesia induced by scopolamine (1.5 mgkg–1 ip),
mecamylamine (20 mgkg–1 ip) and dihydro-β-erythroidine (10 µg per mouse i.c.v.). In the same experimen-
tal conditions, DBO-83 (10 mgkg–1 ip) also prevented baclofen (2 mgkg–1 ip), clonidine (0.125 mgkg–1 ip)
and diphenhydramine (20 mgkg–1 ip) amnesia in mice. The antiamnesic effect of DBO-83 was comparable
to that exerted by nicotine (2 mgkg–1 ip), physostigmine (0.2 mgkg–1 ip), and the nootropic drug, piracetam
(30 mgkg–1 ip). In the antiamnesic dose-range, DBO-83 did not impair mouse motor coordination and
spontaneous motility, as revealed, respectively, by the Animex apparatus and rotarod test. These results
demonstrated the ability of DBO-83 to modulate memory functions and suggest that DBO-83 could be
useful in the treatment of cognitive deficits. Drug Dev. Res. 45:45–51, 1998. © 1998 Wiley-Liss, Inc.
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INTRODUCTION
Recently, there has been increased interest in the
role of nicotinic neurotransmission in cognitive deficits
associated with Alzheimer’s disease and in the therapeutic
potential of agents that activate neuronal nicotinic recep-
tors. The potential for the development of therapies for
Alzheimer’s disease that work through the stimulation of
nicotinic receptors is suggested by the observation that
nicotine improves some aspects of cognitive function in
patients affected by Alzheimer’s disease [Newhouse et
al., 1988; Jones et al., 1992; Wilson et al., 1995]. There is
now substantial evidence that nicotinic neurotransmis-
sion plays an important role in cognitive function [Levin,
1992]. In rats, nicotine reverses cognitive impairments
due to basal forebrain lesions [Hodges et al., 1991;
Decker et al., 1992] and age [Arendash et al., 1995; Socci
et al., 1995] and in mice prevents mnemonic deficits in-
duced by pharmacological treatments such as mecamyl-
amine [Zarrindast et al., 1996] and scopolamine [Coyle
et al., 1987].
The beneficial effects of nicotine have also been
exhibited by other nicotinic agonists. (-)-Lobeline [Decker
et al., 1993], ABT-418 [Decker et al., 1994], ABT-089
[Decker et al., 1997], AG-4 [Marchese et al., 1997], and
GTS-21 [Meyer et al., 1994] have been reported to ame-
liorate memory impairments in rodents in some experi-
mental paradigms.
Within the framework of the research for new nico-
tinic agonists potentially useful in the prevention of re-
duced cognitive performance, it was decided to use
DBO-83 (3-[p-Cl-pyridazine-6-yl]-diazabicyclo[3.2.1]-
octane). The present work was designed to verify the
ability of this new nicotinic agonist [Ghelardini et al.,
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1997; Barlocco et al., 1998] to prevent pharmacologically
induced amnesia in the mouse passive-avoidance test.
MATERIALS AND METHODS
Animals
Male Swiss albino mice (23–30 g) from Morini (San
Polo d’Enza, Italy) breeding farms were used. Fifteen
mice were housed per cage. The cages were placed in
the experimental room 24 h before the test for acclimati-
zation. The animals were kept at 23 ± 1°C with a 12-h
light/dark cycle, light at 7 AM, with food and water ad
libitum. All experiments were carried out according to
the guidelines of the European Community Council for
experimental animal care.
Passive-Avoidance Test
The test was performed according to the step-
through method described by Jarvik and Kopp [1967].
The apparatus consisted of a two-compartment acrylic
box with a lighted compartment connected to a darkened
one by a guillotine door. Mice, as soon as they entered
the dark compartment, received a punishing electrical
shock (0.5 mA, 1 sec). The latency times for entering the
dark compartment were measured in the training test
and after 24 h in the retention test. For memory dis-
ruption, animals were injected with amnesic drugs.
Scopolamine, mecamylamine, dihydro-β-erythroidine,
clonidine, baclofen, diphenhydramine were i.p. in-
jected immediately after the training session. To im-
prove memory animals were treated, 20 min before
the training session, with DBO-83, piracetam, nico-
tine, or physostigmine. The drug administration sched-
ule was chosen on the basis of preliminary experiments
in which the time-course for every compound was
determined. The maximum entry latency allowed in
the training session was 30 sec for mice, whereas in
the retention session the entrance latency allowed was
120 sec. The memory degree of received punishment
was expressed as latencies recorded in the retention
and training sessions.
Spontaneous Activity Meter (Animex)
Locomotor activity in mice was quantified using an
Animex activity meter Type S (LKB, Farad, Sweden) set
to maximum sensitivity. Every movement of the mice,
which were placed on the top of the Animex activity
meter, produced a signal due to variation in inductance
and capacity of the apparatus resonance circuit. Signals
were automatically converted to numbers. On the day of
the experiment the mice were treated and then the cage,
containing five mice, was put on the measuring platform.
Activity counts were made for 5 min at 15-min intervals
for 45 min (total of three sessions) starting immediately
after injection of the drug. Because of the arbitrary scale
adopted to quantify movements, drug-treated mice were
always compared with saline-treated ones.
Rotarod Test
The apparatus consisted of a base platform and a
rotating rod of 3 cm diameter with a nonslippery surface.
This rod was placed at height of 15 cm from the base.
The rod, 30 cm in length, was divided into five equal
sections by six disks. Thus, up to five mice were tested
simultaneously on the apparatus, with a rod-rotating
speed of 16 r.p.m. The integrity of motor coordination
was assessed on the basis of endurance time of the ani-
mals on the rotating rod. One day before the test, the
animals were trained twice. On the day of the test only
the mice that were able to stay balanced on the rotating
rod between 70 and 120 s (cutoff time) were selected for
testing. The performance time was measured before and
at various times after treatment.
Intracerebroventricular Injection Technique
Intracerebroventricular (icv) administration was
performed in mice under ether anesthesia using isotonic
saline as solvent, according to the method described by
Haley and McCormick [1957]. Briefly, under anesthesia
mice were grasped firmly by the loose skin behind the
head. A 0.4 mm external diameter hypodermic needle
attached to a 10 µl syringe was inserted perpendicularly
through the skull to a depth of no more than 2 mm into
the brain of the mouse, where 5 µl were then adminis-
tered. The injection site was 1.5 mm from either side of
the midline on a line drawn through to the anterior base
of the ears. To ascertain that the drugs were adminis-
tered exactly into the cerebral ventricle, some mice were
icv injected with 5 µl of diluted 1:10 India ink and their
brains examined macroscopically after sectioning. The
accuracy of the injection technique was evaluated and
95% were correct injections.
Reagents and Compounds
The following compounds were used: DBO-83 (3-
[p-Cl-pyridazine-6-yl]-diazabicylo[3.2.1]octane), pre-
pared at the Institute of Pharmaceutical and Toxicological
Sciences, University of Milan; diphenhydramine hydro-
chloride (de Angeli); scopolamine hydrobromide,
mecamylamine hydrochloride, clonidine hydrochloride
(RBI, Natick, MA), nicotine hydrogentartrate, dihydro-
β-erythroidine (Fluxa), baclofen, piracetam, physostig-
mine hemisulphate (Sigma, St. Louis, MO).
Compounds were dissolved in isotonic (NaCl 0.9%)
saline solution and concentrations were prepared in such
a way that the necessary dose could be administered in a
volume of 5 µl per mouse by intracerebroventricular (icv)
injection and 10 ml kg–1 by intraperitoneal (ip) injection.
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Statistical Analysis
All experimental results are given as the mean ±
SEM. Analysis of variance (ANOVA), followed by Fisher’s
Protected Least Significant Difference (PLSD) procedure
for post-hoc comparison was used to verify significance
between two means. Data were analyzed with the
StatView software for the Macintosh (1992). P values of
less than 0.05 were considered significant.
RESULTS
Prevention of Amnesia by DBO-83
The nicotinic agonist DBO-83 dose-dependently
prevented amnesia induced by the antimuscarinic drug
scopolamine (1.5 mgkg–1 ip) in the mouse passive-avoid-
ance test (Fig. 1). DBO-83, at the dose of 0.5 mgkg–1 ip,
was completely ineffective, whereas at the doses of 1 and
5 mgkg–1 ip, it prevented antimuscarinic amnesia, reach-
ing entrance latency values comparable to those produced
by saline-treated mice.
The maximum antiamnesic effect of DBO-83 (5
mgkg–1 ip) was also equal to that produced by the anticho-
linesterase inhibitor, physostigmine (0.2 mgkg–1 ip), and
the well-known nootropic drug, piracetam (30 mgkg–1 ip)
(Fig. 1). However, at active doses DBO-83 it did not en-
hance the entrance latency in unamnesic mice in com-
parison with the control group (Fig. 1). There were no
differences observed in the various entrance latencies of
every group in the training session of the passive-avoid-
ance test (Fig. 1). The administration of DBO-83 (range
1–5 mgkg–1 ip) also antagonized the memory disruption
produced by the two nicotinic antagonists, mecamylamine
(20 mgkg–1 ip) and dihydro-β-erythroidine (10 µg per
mouse icv), (Fig. 2, 3). Doses of DBO-83 of 5–10 mgkg–1 ip
were necessary to prevent amnesia induced by the α2 ago-
nist, clonidine (0.125 mgkg–1 ip), the GABAB agonist,
baclofen (2 mgkg–1 ip), and the H1 antagonist, diphenhy-
dramine (20 mgkg–1 ip) (Fig. 4) in the mouse passive-avoid-
ance test. The maximum antiamnesic effect was reached at
the dose of 10 mgkg–1 ip. DBO-83 was active in facilitating
memory similar to nicotine in the presence of mecamylamine
and dihydro-β-erythroidine-induced amnesia (Figs. 2, 3).
Effect of DBO-83 on Mouse Rotarod Test
and Mouse Animex Apparatus
It should be noted that DBO-83 elicited its modu-
latory effect on cognitive processes without changing the
Fig. 1. Dose–response curves of DBO-83 in comparison with piracetam
and physostigmine on amnesia induced by scopolamine (1.5 mgkg–1 ip) in
the mouse passive-avoidance test. DBO-83, piracetam, and physostigmine
were administered ip 20 min before the training session while scopola-
mine was injected immediately afterwards. The number of mice is inside
the column. *P < 0.01 in comparison with scopolamine-treated mice.
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animal’s gross behavior, motor coordination, or sponta-
neous motility as revealed, respectively, by using the
mouse rotarod test (Table 1) and the Animex apparatus
(Fig. 5). DBO-83, administered at the highest active
doses, did not reduce the endurance time on the rotating
rod in comparison with saline-treated mice (Table 1).
The spontaneous motility of mice were unmodified
by DBO-83 administration (10 mgkg–1 ip) as revealed by
the Animex apparatus in comparison with saline-treated
mice (Fig. 5).
DISCUSSION
The present results describe acute effects observed
with DBO-83 on experimentally impaired memory in
mice. DBO-83 has been demonstrated to prevent amne-
sia induced by pharmacological treatments in the pas-
sive-avoidance test.
That stimulation of the nicotinic system improves
cognitive processes has long been observed [Tilson et al.,
1988; Hodges et al., 1991; Decker et al., 1992; Socci et
al., 1995]. On the other hand, the administration of the
nicotinic ACh receptor antagonist, mecamylamine, pro-
duces a dose-dependent impairment of cognitive perfor-
mance in mice [Dilts and Berry, 1967; Zarrindast et al.,
1996], rats [Elrod and Buccafusco, 1991; Bammer, 1982],
monkeys [Elrod et al., 1988], and humans [Newhouse et
al., 1992, 1994]. Also, the nicotinic blocker dihydro-β-
erythroidine disrupted acquisition in spatial information
in the rat Morris water maze [Curzon et al., 1996]. The
administration of scopolamine, an unselective muscar-
inic ACh receptor antagonist, results in impaired learn-
ing and memory in humans [Frumier et al., 1976] and
animals [Dilts and Berry, 1967; Levin and Bowman, 1986].
Amnesia can also be induced by modulating neu-
rotransmitter systems other than the cholinergic. The α2
antagonist clonidine is able to induce an amnesic effect
in mice and rats in the passive-avoidance test [Coyce et
al., 1987]. GABA is the main inhibitory neurotransmitter
in the brain and it plays an important role in learning
and memory. The activation of GABAA receptors impairs
memory performance [Jerusalinsky et al., 1994] and the
stimulation of GABAB receptors by baclofen disrupts
memory after systemic, intra-amygdala or intraseptal
administration [Swartzwelder et al., 1987; Castellano et
al., 1989; Stackman and Walsh, 1994]. The antihistaminics
are known to exert a variety of effects on the central ner-
vous system. Central depression usually accompanies
therapeutic doses of the H1 antagonists, which appears
Fig. 2. Dose–response curves of DBO-83 in comparison with nicotine
on amnesia induced by mecamylamine (20 mgkg–1 ip) in the mouse pas-
sive-avoidance test. DBO-83 and nicotine were administered ip 20 min
before the training session while mecamylamine was injected immedi-
ately afterwards. The number of mice is inside the column. *P < 0.01 in
comparison with mecamylamine-treated mice.
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Fig. 4. Dose–response curves of DBO-83 in comparison with piracetam
on amnesia induced in the mouse by clonidine (0.125 mgkg–1 ip), baclofen
(2 mgkg–1 ip) and diphenhydramine (20 mgkg–1 ip) in the passive-avoid-
ance test. DBO-83 and piracetam were administered ip 20 min before
the training session while the other drugs were injected immediately af-
terwards. Each column represents the mean of at least 15 mice. *P <
0.01 in comparison with amnesic drug-treated animals.
Fig. 3. Dose–response curves of DBO-83 in comparison with nicotine on
amnesia induced by dihydro-β-erythroidine (10 µg per mouse icv) in the
mouse passive avoidance test. DBO-83 and nicotine were administered ip
20 min before the training session while dihydro-β-erythroidine was in-
jected immediately afterwards. The number of mice is inside the column.
*P < 0.01 in comparison with dihydro-β-erythroidine-treated mice.
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to be related to occupancy of cerebral H1
 receptors; im-
pairment of cognitive functions is a common manifesta-
tion [Simons and Simons, 1994]. Furthermore, the
administration of the cerebral H1 antagonist diphenhy-
dramine also induces amnesia in animals [Kamei et al.,
1990; Galeotti et al., 1998].
DBO-83 was able to prevent amnesia induced by
the administration of scopolamine, mecamylamine,
dihydro-β-erytroidine, clonidine, baclofen, and diphen-
hydramine. Thus, DBO-83 counteracts amnesia not only
induced by nicotinic antagonists, but also that obtained
independently from a nicotinic blockade.
DBO-83 is also endowed with antinociceptive prop-
erties [Ghelardini et al., 1997; Barlocco et al., 1998] and
the time-course of the antiamnesic activity of DBO-83
was equal to that observed for its antinociceptive action,
reaching its maximum between 15 and 30 min after in-
jection (data not shown). Therefore, in the learning and
memory experiments DBO-83 was administered 20 min
before the training session.
In the first session, the latency to enter the dark
compartment of the light-dark box in the passive-avoid-
ance test was not modified by the administration of DBO-
83. This observation was confirmed by evaluation of the
behavioral parameters in mice. DBO-83, at the highest
doses used, did not impair motor coordination, as re-
vealed by the rotarod test, or modify spontaneous motil-
ity, as indicated by the Animex apparatus. Furthermore,
DBO-83 did not elicit the typical tremors produced by
injection of nicotine. In other words, DBO-83 is able to
counteract amnesia in a physiological manner.
In conclusion, these results indicate the ability of
DBO-83 to modulate memory processes. On these bases,
DBO-83 could be considered a new potential antiamnesic
drug, useful in the treatment of cognitive disorders.
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